A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Allergan

Status: Completed

Conditions: Ocular Hypertension; Glaucoma, Open-Angle

Treatments: Drug: bimatoprost 0.01% ophthalmic solution

Study type: Observational

Funder types: Industry

Identifiers

NCT01589510

MAF/AGN/OPH/GLA/034

Details and patient eligibility

About

A study of Lumigan® 0.01% as administered in standard practice for patients with POAG or OHT. All treatment decisions, care and diagnostic procedures provided are at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.

Enrollment: 419 patients

Sex: All

Ages: 16+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of POAG or OHT
• Prescribed Lumigan® 0.01%

Exclusion criteria

• None

Trial design

419 participants in 1 patient group

Lumigan® 0.01%

Description:

Lumigan® 0.01% (bimatoprost 0.01% ophthalmic solution) as prescribed by physician per standard practice for up to 14 weeks.

Treatment:

Drug: bimatoprost 0.01% ophthalmic solution